To promote radiopharmaceutical uptake by the tumor, long-acting somatostatin is discontinued for 4 weeks prior to therapy, and short acting somatostatin is discontinued 24 h prior to therapy (Jia et al. 2022; Strosberg et al. 2018). The gene discussed is SST; the disease is neoplasm.